- Home
- BGLC vs KZIA Comparison
BGLC vs KZIA Comparison
Compare BGLC & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGLC
- KZIA
- Stock Information
- Founded
- BGLC 2017
- KZIA 1994
- Country
- BGLC Malaysia
- KZIA Australia
- Employees
- BGLC N/A
- KZIA N/A
- Industry
- BGLC Medical Specialities
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- BGLC Health Care
- KZIA Health Care
- Exchange
- BGLC Nasdaq
- KZIA Nasdaq
- Market Cap
- BGLC 5.8M
- KZIA 6.0M
- IPO Year
- BGLC N/A
- KZIA 1999
- Fundamental
- Price
- BGLC $0.25
- KZIA $0.80
- Analyst Decision
- BGLC
- KZIA Strong Buy
- Analyst Count
- BGLC 0
- KZIA 2
- Target Price
- BGLC N/A
- KZIA $11.50
- AVG Volume (30 Days)
- BGLC 1.5M
- KZIA 334.9K
- Earning Date
- BGLC 05-14-2025
- KZIA 04-11-2025
- Dividend Yield
- BGLC N/A
- KZIA N/A
- EPS Growth
- BGLC N/A
- KZIA N/A
- EPS
- BGLC N/A
- KZIA N/A
- Revenue
- BGLC $9,259,858.00
- KZIA $1,655,324.00
- Revenue This Year
- BGLC N/A
- KZIA N/A
- Revenue Next Year
- BGLC N/A
- KZIA N/A
- P/E Ratio
- BGLC N/A
- KZIA N/A
- Revenue Growth
- BGLC N/A
- KZIA 248000.00
- 52 Week Low
- BGLC $0.21
- KZIA $0.76
- 52 Week High
- BGLC $1.00
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- BGLC 35.57
- KZIA 37.02
- Support Level
- BGLC $0.23
- KZIA $0.91
- Resistance Level
- BGLC $0.29
- KZIA $1.05
- Average True Range (ATR)
- BGLC 0.02
- KZIA 0.08
- MACD
- BGLC -0.01
- KZIA -0.00
- Stochastic Oscillator
- BGLC 20.22
- KZIA 12.34
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.